Andrea Visentin, MD, discusses the relevance of cost analysis in guiding treatment sequencing for patients with chronic lymphocytic leukemia.
Andrea Visentin, MD
Advertisement
Andrea Visentin, MD, is , an oncologist in the Department of Medicine, Hematology Unit, at the University of Padova in Italy.
Articles by Andrea Visentin, MD
Andrea Visentin, MD, discusses data from an Italian cost analysis of treatment sequencing in CLL.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5